Role of Trop-2 as an Actionable Biomarker in Solid Tumors | Supplements And Featured Publications

ESMO 2020 Highlights With Cora Sternberg, MD, FACP

October 30, 2020

TROPHY U-01 cohort 1 is a phase 2 open-label study of sacituzumab govitecan in patients with metastatic urothelial cancer and disease progression after both platinum-based regimens and checkpoint inhibitors.

x